Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Irritable Bowel Syndrome: HELP
Articles from Virginia
Based on 13 articles published since 2008

These are the 13 published articles about Irritable Bowel Syndrome that originated from Virginia during 2008-2019.
+ Citations + Abstracts
1 Review Updated review of current pharmacological and non-pharmacological management of irritable bowel syndrome. 2018

Rawla, Prashanth / Sunkara, Tagore / Raj, Jeffrey Pradeep. ·Department of Internal Medicine, SOVAH Health, Martinsville, VA 24115, USA. Electronic address: rawlap@gmail.com. · Division of Gastroenterology and Hepatology, Mercy Medical Center, Des Moines, IA 50314, USA. · Department of Clinical Pharmacology, King Edward Memorial Hospital, Seth GS Medical College, Mumbai 400013, India. ·Life Sci · Pubmed #30290187.

ABSTRACT: Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract that is usually associated with chronic abdominal pain and altered bowel habits. The two spectra of the disease include constipation-predominant IBS and Diarrhea-predominant IBS. Earlier it was thought to be an unexplained brain-gut disorder, but of late, various underlying causes suggesting primary gut disturbance have been identified. The initial management primarily includes the non-pharmacological measures such as dietary modifications, increasing physical activity, and psychological therapy. Pharmacological management is adjunct to non-pharmacological management, and the drug is chosen based on the predominant symptom of bowel habit whether constipation or diarrhea. In this review, we aim to update the readers on the currently available management options in the treatment of IBS - both pharmacological and non-pharmacological options. Further, for the various pharmacological treatments, we summarize the clinical pharmacology, indications, contraindications, adverse effects and use in pregnancy.

2 Review New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. 2018

Bajaj, Jasmohan S / Barbara, Giovanni / DuPont, Herbert L / Mearin, F / Gasbarrini, Antonio / Tack, Jan. ·Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA, USA. · Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. · Center for Infectious Diseases, The University of Texas School of Public Health, Baylor College of Medicine, Kelsey Research Foundation, Houston, TX, USA. · Institute of Functional and Motor Digestive Disorders, Centro Médico Teknon, Barcelona, Spain. · Catholic University of Rome, Gemelli University Hospital, Rome, Italy. Electronic address: antonio.gasbarrini@unicatt.it. · Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, University of Leuven, Belgium; Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium. ·Dig Liver Dis · Pubmed #29807873.

ABSTRACT: Digestive diseases are a broad range of chronic disorders that substantially and negatively impact the patients' quality of life. Here, we review our current understanding on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease, with a special focus on the gut microbiota composition associated with these disorders. Furthermore, we review the current clinical practice for their therapeutic treatments, including probiotics, diet change, non-adsorbable disaccharides, and antibiotics. We highlight that broad-spectrum non-adsorbable antibiotics, such as rifaximin, are quite effective and safe for the treatment of all essayed digestive diseases.

3 Review Gastrointestinal Conditions in the Female Athlete. 2017

Diduch, Barry Kent. ·Department of Sports Medicine, James Madison University, 261 Bluestone Drive MSC 2301, Harrisonburg, VA 24401, USA. Electronic address: diduchbk@jmu.edu. ·Clin Sports Med · Pubmed #28886820.

ABSTRACT: Exercise can have significant effects on gastrointestinal diseases. Regular, moderate exercise can impart beneficial effects for the intestinal microbiome, irritable bowel syndrome symptoms, and inflammatory bowel disease. High-intensity training or prolonged endurance training, on the other hand, can have negative effects on these same entities. Female athletes report a higher prevalence of irritable bowel syndrome and celiac disease, and furthermore, have gastrointestinal symptoms modulated by the menstrual cycle. Management of gastrointestinal problems in the athletic population is widespread and includes training adjustments, dietary measures, and medicine management of symptoms.

4 Review Irritable bowel syndrome: a "mesh" of a situation. 2012

Barnes, Matthew G. ·Medical Corps, United States Air Force, Dewitt Army Hospital, Fort Belvoir, VA, USA. ·J Am Board Fam Med · Pubmed #22218633.

ABSTRACT: The diagnosis of irritable bowel syndrome (IBS) frequently is made after the exclusion of a mechanical etiology for a patient's symptoms. This case demonstrates that IBS symptoms can be caused by a rare complication of a common surgery: mesh herniorrhaphy repair. The patient is a 50-year-old woman who underwent periumbilical Marlex mesh herniorrhaphy 13 years before presentation. After her operation, the patient developed constipation (approximately one bowel movement per week) alternating with diarrhea for approximately 10 years. An abdominal radiograph showed large amounts of stool, and after a normal colonoscopy the patient was diagnosed with IBS. The patient was treated with tegaserod (Zelnorm) and polyethylene glycol (MiraLAX), which did not palliate her symptoms. The patient presented with obstructive symptoms and physical findings of an incarcerated umbilical hernia. A computed tomography (CT) scan of the abdomen confirmed an umbilical hernia involving a segment of small bowel with surrounding fecalization of enteric contents. During operative repair, the patient was found to have Marlex mesh fully eroded into the lumen of the small bowel, causing a partial obstruction. The involved section of small bowel was resected, and during serial follow-up the patient had complete resolution of her IBS-like symptoms. A discussion follows regarding the implications of mesh migration, and questions are posed for future research.

5 Review Irritable bowel syndrome: aeromedical considerations. 2011

Rayman, Russell B. ·Aerospace Medical, PLC, Alexandria, VA, USA. USA. rrayman@aerospace-medical.com ·Aviat Space Environ Med · Pubmed #22097642.

ABSTRACT: Irritable bowel syndrome (IBS) is a gastrointestinal disorder diagnosed in accordance with the Rome III criteria. The pathophysiology of this illness is not well defined and there are no known structural abnormalities, biomedical markers, nor inflammatory causes to explain the symptoms. There are a number of serious illnesses, such as colon cancer, ulcerative colitis, and celiac disease that mimic IBS. If the Rome III criteria are satisfied and there are no alarm features of more serious illness, an in-depth workup is not necessary. There are numerous treatment regimens for IBS, none of which are curative nor offer universal relief. Some of the treatment regimens, such as antispasmodics and antidiarrheals, are not suitable for aviators because of anticholinergic effects and sedation. The aeromedical disposition decision is always challenging because of the vagaries of this illness. In general, a more liberal policy for pilots in civil aviation would be in order as long as symptoms are not frequent nor severe and not requiring antispasmodics or antidiarrheals while flying. A more conservative policy is in order for military pilots, possibly requiring restriction to multiseat aircraft.

6 Review When to reconsider the diagnosis of irritable bowel syndrome. 2011

Hammerle, Christopher W / Crowe, Sheila E. ·Division of Gastroenterology and Hepatology, University of Virginia, PO Box 800708, Charlottesville, VA 22908-0708, USA. ·Gastroenterol Clin North Am · Pubmed #21601781.

ABSTRACT: Irritable bowel syndrome (IBS) is a highly prevalent disorder characterized by nonspecific symptoms that can mimic other common medical conditions. A careful history and physical examination may reveal clues that suggest a coexisting or alternative diagnosis, such as small intestinal bacterial overgrowth or celiac disease (CD). Testing for bacterial overgrowth has limitations, but emerging data suggest that antibiotics may be of some benefit in patients with IBS with diarrhea and bloating. CD seems to have a higher prevalence in patients with IBS. Some patients with IBS may have symptomatic improvement on gluten-restricted diets, without histologic or serologic evidence of CD.

7 Review Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine. 2011

Spiegel, David R / Kolb, Richard. ·Department of Psychiatry and Behavioral Sciences, Eastern Virginia Medical School, Norfolk, VA 23507, USA. spiegedr@evms.edu ·Clin Neuropharmacol · Pubmed #21242743.

ABSTRACT: Irritable bowel syndrome (IBS) is a functional gastrointestinal tract disorder characterized by recurrent abdominal pain or discomfort, where the onset is associated with either a change in form of stool or its frequency and is often improved with defecation. Alosetron, a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, was an effective drug in treating women with diarrhea-predominant IBS. However, the drug was removed from the United States market because of its association with ischemic colitis and serious complications related to severe constipation. Presented here is a case report of a 66-year-old woman with a history of panic disorder and major depression and a 1-year history of IBS-mixed type, which she reported to be "worsened by panic attacks." On the basis that mirtazapine is a potent 5-HT3 receptor antagonist and has demonstrated pain relief from somatic symptoms, we treated our patient with mirtazapine, which seems to have decreased her diarrhea and constipation symptoms, and her psychopathological symptoms.

8 Clinical Trial Influence of comorbidities on improvement of fibromyalgia symptoms when treated with acupuncture: a short report. 2008

Singh, Betsy B / Khorsan, Raheleh / Vinjamury, Sivarama Prasad. ·Medicus Research LLC, Midlothian, Virginia, USA. ·Altern Ther Health Med · Pubmed #18780581.

ABSTRACT: BACKGROUND: Fibromyalgia syndrome (FMS) is associated with chronic widespread pain, mood alteration, and disability. A definitive treatment plan has not been identified. The genesis of FMS is unclear and generally occurs in women. PURPOSE: To determine whether patient-identified most disruptive comorbidity (MDC) secondary to FMS may have mediated recovery for individual patients. This is a probative analysis of data from an effectiveness study published in the March 2006 issue of Alternative Therapies in Health and Medicine. (2006;12(2):34-41.) METHODS: The American College ofRheumatology (ACR) criteria for FMS was used in participant selection; 21 participants completed the study. RESULTS: The original outcome study indicated significant changes on standardized measures using specific points and numbers of treatment within an 8-week period. The preliminary data on influence ofMDC on improvement were differential related to self-report MDC by patients. CONCLUSIONS: For all MDCs combined, participants experienced significant improvement at 8 weeks of treatment. Participants with irritable bowel syndrome as their MDC generally had a lower percentage of improvement than other MDC cohort groups. This finding has implications for treatment.

9 Article Epidemiology and self-treatment of travelers' diarrhea in a large, prospective cohort of department of defense beneficiaries. 2015

Lalani, Tahaniyat / Maguire, Jason D / Grant, Edward M / Fraser, Jamie / Ganesan, Anuradha / Johnson, Mark D / Deiss, Robert G / Riddle, Mark S / Burgess, Timothy / Tribble, David R / Anonymous3940814. ·Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA; Division of Infectious Diseases, Naval Medical Center, Portsmouth, VA, USA. ·J Travel Med · Pubmed #25483360.

ABSTRACT: BACKGROUND: Infectious diarrhea is a common problem among travelers. Expert guidelines recommend the prompt use of antibiotics for self-treatment of moderate or severe travelers' diarrhea (TD). There is limited data on whether travelers follow these self-treatment guidelines. We evaluated the risk factors associated with TD, the use of TD self-treatment, and the risk of irritable bowel syndrome (IBS) during travel. METHODS: Department of Defense beneficiaries traveling outside the United States for ≤6.5 months were enrolled in a prospective cohort study. Participants received pre- and post-travel surveys, and could opt into a travel illness diary and follow-up surveys for symptoms of IBS. Standard definitions were used to assess for TD and IBS. Suboptimal self-treatment was defined as the use of antibiotics (with or without antidiarrheal agents) for mild TD, or the use of antidiarrheals alone or no self-treatment in cases of moderate or severe TD. RESULTS: Twenty-four percent of participants (270/1,120) met the criteria for TD. The highest incidence was recorded in Africa [8.6 cases/100 person-weeks, 95% confidence interval (CI): 6.7-10.5]. Two hundred and twelve participants with TD provided information regarding severity and self-treatment: 89 (42%) had mild TD and 123 (58%) had moderate or severe TD. Moderate or severe TD was independently associated with suboptimal self-treatment [OR 10.4 (95% CI: 4.92-22.0)]. Time to last unformed stool did not differ between optimal and suboptimal self-treatment. IBS occurred in 4.5% (7/154) of TD cases and in 3.1% (16/516) of cases without TD (p = 0.39). Among TD cases, a lower incidence of IBS was noted in participants who took antibiotics [4.8% (5/105) vs 2.2% (1/46)] in those who did not, but the difference did not reach statistical significance (p = 0.60). CONCLUSIONS: Our results suggest the underutilization of antibiotics in travelers with moderate or severe TD. Further studies are needed to systematically evaluate pre-travel instruction and traveler adherence to self-treatment guidelines, and the impact of suboptimal self-treatment on outcomes.

10 Article Prevalence, health care utilization, and costs of fibromyalgia, irritable bowel, and chronic fatigue syndromes in the military health system, 2006-2010. 2014

Jeffery, Diana D / Bulathsinhala, Lakmini / Kroc, Michelle / Dorris, Joseph. ·Department of Defense, Defense Health Agency, 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042-5101. · U.S. Army Research Institute of Environmental Medicine, Kansas Street, Natick, MA 01760-5007. · Altarum Institute, 4401 Ford Avenue #800, Alexandria, VA 22302. · Altarum Institute, 3520 Green Court #300, Ann Arbor, MI 48105. ·Mil Med · Pubmed #25181721.

ABSTRACT: OBJECTIVE: We compared prevalence, health care utilization, and costs over time for nonelderly adults diagnosed with fibromyalgia syndrome (FMS), irritable bowel syndrome (IBS), and chronic fatigue syndrome (CFS) in relation to timing of federal approvals for FMS drugs. DATA SOURCE: We used military health care claims from October 2006 to September 2010. STUDY DESIGN/ANALYSIS: Retrospective, multiple-year comparisons were conducted using trend analyses, and time series regression-based generalized linear models. RESULTS: Over 5 years, FMS prevalence rates increased from 0.307% to 0.522%, whereas IBS and CFS prevalence rates remained stable. The largest increase in FMS prevalence occurred between 2007 and 2008. Health care utilization was higher for FMS cases compared to IBS and CFS cases. Over 5 years, the total cost for FMS-related care increased $163.2 million, whereas IBS costs increased $14.9 million and CFS cost increased $3.7 million. Between 2006 and 2010, total pharmacy cost for FMS cases increased from $55 million ($3,641/person) to $96.3 million ($3,557/person). CONCLUSION: Although cause and effect cannot be established, the advent of federally approved drugs for FMS in concert with pharmaceutical industry marketing of these drugs coincide with the observed changes in prevalence, health care utilization, and costs of FMS relative to IBS and CFS.

11 Article Case study: aphthous ulcers in a 14-year-old girl. 2011

Krebs, Karlin T. ·Primary Care Clinic, Child Health Associates, Warrenton, VA, USA. ·Pediatr Nurs · Pubmed #21739742.

ABSTRACT: Recurrent aphthous ulcers (RAUs), also known as canker sores, aphthous stomatitis, or aphthae, are a very common and often painful condition presenting in primary care. The majority of aphthous ulcers are benign, time-limited (7 to 14 days), and in some cases, require pain management until healed. However, RAUs can be a manifestation of a serious health condition, such as an autoimmune disorder, human immunodeficiency virus, infection, and hematologic or oncologic conditions. Initially, the most important priority in caring for these patients is to obtain a complete history and physical examination to rule out systemic disease and lead to an accurate diagnosis and plan of care.

12 Article Conquering IBS in women: the clinician's pursuit of optimum management strategies. 2008

Peura, David A / Rose, Suzanne / Miller, Howard A. ·University of Virginia Health Sciences Center, Charlottesville, VA, USA. ·Postgrad Med · Pubmed #18845915.

ABSTRACT: -- No abstract --

13 Minor Utility of Fecal Markers to Diagnose and Monitor Inflammatory Bowel Diseases. 2015

Sorrentino, Dario / Franck, Christopher. ·Division of Gastroenterology, Virginia Tech-Carilion School of Medicine, Roanoke, Virginia, USA. · Department of Clinical and Experimental Medical Sciences, University of Udine School of Medicine, Udine, Italy. · Laboratory for Interdisciplinary Statistical Analysis (LISA), Department of Statistics, Virginia Tech, Blacksburg, Virginia, USA. ·Am J Gastroenterol · Pubmed #26673502.

ABSTRACT: -- No abstract --